Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Effect of Food on the Pharmacokinetics of HRS4800 in Healthy Male Participants

X
Trial Profile

A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Effect of Food on the Pharmacokinetics of HRS4800 in Healthy Male Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HRS 4800 (Primary)
  • Indications Pain
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Atridia
  • Most Recent Events

    • 28 Mar 2022 Status changed from recruiting to completed.
    • 28 Mar 2022 The primary endpoints changed from Incidence of AEs, severity of AEs, and Change in diastolic blood pressure and systolic blood pressure from baseline, diastolic blood pressure and systolic blood pressure from baseline, respiratory rate from baseline,QT interval from baseline by ECG, corrected QT (QTc) interval from baseline by ECG, and P-R interval from baseline by ECG to HRS4800 Single Dose Escalation - Safety, AUC0-t, AUC0-infi, Tmax, Cmax, t1/2,CL/F, and Vz/F, according to Clinicaltrials.gov
    • 28 Jul 2021 Planned End Date changed from 1 Oct 2021 to 1 Dec 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top